Breaking News

ABL Expands GMP Viral Vector Mfg. Capacity

Acquires state-of-the-art facility in Lyon, France

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

ABL, Inc., a global contract manufacturing organization (CMO) that advances vaccines and therapies from clinical development to the commercial market, has acquired through its wholly-owned subsidiary, ABL Europe SAS, a 6,500 square meter GMP manufacturing site located in Lyon, France.    ABL Europe provides viral vector GMP contract manufacturing services for oncolytic, vaccine and gene therapy projects in all stages of clinical development through to commercial launch. Maintaining synergy wit...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters